Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Nowotwory. Journal of Oncology
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Editorial Office Manuscript Submission Reviewers 2023 Best Original Paper Award

open access

Vol 71, No 2 (2021)
Review paper
Published online: 2021-04-06
View PDF Download PDF file
Get Citation

Neoadjuvant therapy for breast cancer patients and its impact on surgical treatment and radiotherapy (part 2.)

Zbigniew I. Nowecki1, Agnieszka Jagiełło-Gruszfeld1, Katarzyna Pogoda1, Anna Niwińska1, Wojciech P. Olszewski2, Paweł Winter1, Rafał Matkowski34, Wojciech M. Wysocki567
DOI: 10.5603/NJO.2021.0021
·
Nowotwory. Journal of Oncology 2021;71(2):79-93.
Affiliations
  1. Department of Breast Cancer & Reconstructive Surgery, M. Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
  2. Department of Pathology and Laboratory Diagnostics, M. Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
  3. Department of Oncology, Wroclaw Medical University, Wroclaw, Poland
  4. Breast Unit, Wrocław Comprehensive Cancer Center, Wroclaw, Poland
  5. General, Oncological and Vascular Surgery Clinic, 5th Military Hospital with Polyclinic in Cracow, Cracow, Poland
  6. Chair of Surgery, Faculty of Medicine and Health Science, A. Frycz Modrzewski Krakow University, Cracow, Poland
  7. Scientific Editing, M. Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

open access

Vol 71, No 2 (2021)
Review article
Published online: 2021-04-06

Abstract

Neoadjuvant therapy (NAT) is increasingly applied in patients with initially inoperable breast cancers and, frequently, in those with tumours that are initially operable, too. In most cases, the response to the applied NAT affects the scope of surgical treatment and radiotherapy, and in some situations also the complementary systemic postoperative treatment. The available studies indicate importance of response to NAT within the breast and regional lymph nodes. Assessment of response to treatment allows personalization of treatment and in some cases a change of therapy, which improves long-term outcomes. This article summarizes the current rules of conduct in patients with early breast cancer qualified for neoadjuvant thera­py, paying attention to the practical aspects and possibilities of national health insurance-covered therapies in Poland. It discusses in detail the applied regimens of systemic therapy, surgical techniques, eligibility rules and complementary radiotherapy. Systems for assessing response to neoadjuvant treatment are also presented.

Abstract

Neoadjuvant therapy (NAT) is increasingly applied in patients with initially inoperable breast cancers and, frequently, in those with tumours that are initially operable, too. In most cases, the response to the applied NAT affects the scope of surgical treatment and radiotherapy, and in some situations also the complementary systemic postoperative treatment. The available studies indicate importance of response to NAT within the breast and regional lymph nodes. Assessment of response to treatment allows personalization of treatment and in some cases a change of therapy, which improves long-term outcomes. This article summarizes the current rules of conduct in patients with early breast cancer qualified for neoadjuvant thera­py, paying attention to the practical aspects and possibilities of national health insurance-covered therapies in Poland. It discusses in detail the applied regimens of systemic therapy, surgical techniques, eligibility rules and complementary radiotherapy. Systems for assessing response to neoadjuvant treatment are also presented.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

breast cancer; surgery; systemic therapy; neoadjuvant therapy; adjuvant therapy

About this article
Title

Neoadjuvant therapy for breast cancer patients and its impact on surgical treatment and radiotherapy (part 2.)

Journal

Nowotwory. Journal of Oncology

Issue

Vol 71, No 2 (2021)

Article type

Review paper

Pages

79-93

Published online

2021-04-06

Page views

692

Article views/downloads

679

DOI

10.5603/NJO.2021.0021

Bibliographic record

Nowotwory. Journal of Oncology 2021;71(2):79-93.

Keywords

breast cancer
surgery
systemic therapy
neoadjuvant therapy
adjuvant therapy

Authors

Zbigniew I. Nowecki
Agnieszka Jagiełło-Gruszfeld
Katarzyna Pogoda
Anna Niwińska
Wojciech P. Olszewski
Paweł Winter
Rafał Matkowski
Wojciech M. Wysocki

References (104)
  1. Halsted WS. I. The Results of Operations for the Cure of Cancer of the Breast Performed at the Johns Hopkins Hospital from June, 1889, to January, 1894. Ann Surg. 1894; 20(5): 497–555.
    CrossRefPubMed
  2. Ahmed SH. Safety of neoadjuvant chemotherapy for the treatment of breast cancer. Expert Opin Drug Saf. 2019; 18(9): 817–827.
    CrossRefPubMed
  3. Livingston-Rosanoff D, Schumacher J, Vande Walle K, et al. Does Tumor Size Predict Response to Neoadjuvant Chemotherapy in the Modern Era of Biologically Driven Treatment? A Nationwide Study of US Breast Cancer Patients. Clin Breast Cancer. 2019; 19(6): e741–e747.
    CrossRefPubMed
  4. Kim EY, Do SI, Yun JS, et al. Preoperative evaluation of mammographic microcalcifications after neoadjuvant chemotherapy for breast cancer. Clin Radiol. 2020; 75(8): 641.e19–641.e27.
    CrossRefPubMed
  5. Feliciano Y, Mamtani A, Morrow M, et al. Do Calcifications Seen on Mammography After Neoadjuvant Chemotherapy for Breast Cancer Always Need to Be Excised? Ann Surg Oncol. 2017; 24(6): 1492–1498.
    CrossRefPubMed
  6. Özkurt E, Sakai T, Wong SM, et al. Survival Outcomes for Patients With Clinical Complete Response After Neoadjuvant Chemotherapy: Is Omitting Surgery an Option? Ann Surg Oncol. 2019; 26(10): 3260–3268.
    CrossRefPubMed
  7. Heil J, Pfob A, Sinn HP, et al. Abstract GS5-03: Diagnosing residual disease and pathologic complete response after neoadjuvant chemotherapy in breast cancer patients by image-guided vacuum-assisted breast biopsy: Results of a prospective multicenter trial. General Session Abstracts. 2020.
    CrossRef
  8. Tasoulis M, Lee HB, Yang W, et al. Abstract GS5-04: Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict the presence of residual cancer: A multi-institutional pooled analysis. General Session Abstracts. 2020.
    CrossRef
  9. Basik M, Cecchini R, Santos J, et al. Abstract GS5-05: Primary analysis of NRG-BR005, a phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery. General Session Abstracts. 2020.
    CrossRef
  10. Peeters MJ, Loevezijn Av, Noordaa Mv, et al. Abstract GS5-06: Towards omitting breast surgery in patients with a pathologic complete response after neoadjuvant systemic treatment: interim analysis of the MICRA trial (Minimally Invasive Complete Response Assessment). General Session Abstracts. 2020.
    CrossRef
  11. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018; 19(1): 27–39.
    CrossRefPubMed
  12. Werutsky G, Untch M, Hanusch C, et al. Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. Eur J Cancer. 2020; 130: 92–101.
    CrossRefPubMed
  13. van Bommel A, Spronk P, Mureau M, et al. Breast-Contour-Preserving Procedure as a Multidisciplinary Parameter of Esthetic Outcome in Breast Cancer Treatment in The Netherlands. Ann Surg Oncol. 2019; 26(6): 1704–1711.
    CrossRefPubMed
  14. Chang JM, Kosiorek HE, Dueck AC, et al. Trends in mastectomy and reconstruction for breast cancer; a twelve year experience from a tertiary care center. Am J Surg. 2016; 212(6): 1201–1210.
    CrossRefPubMed
  15. Kolacinska A, Hodorowicz-Zaniewska D, Bocian A, et al. Landscape of oncoplastic breast surgery across Poland. Pol Przegl Chir. 2017; 89(6): 14–19.
    CrossRefPubMed
  16. Flanagan MR, Zabor EC, Romanoff A, et al. A Comparison of Patient-Reported Outcomes After Breast-Conserving Surgery and Mastectomy with Implant Breast Reconstruction. Ann Surg Oncol. 2019; 26(10): 3133–3140.
    CrossRefPubMed
  17. Adamson K, Chavez-MacGregor M, Caudle A, et al. Neoadjuvant Chemotherapy does not Increase Complications in Oncoplastic Breast-Conserving Surgery. Ann Surg Oncol. 2019; 26(9): 2730–2737.
    CrossRefPubMed
  18. Kim EY, Do SI, Yun JS, et al. Preoperative evaluation of mammographic microcalcifications after neoadjuvant chemotherapy for breast cancer. Clin Radiol. 2020; 75(8): 641.e19–641.e27.
    CrossRefPubMed
  19. Macdonald S, Oncology R, General M. Breast Cancer Breast Cancer. J R Soc Med. 2016; 70: 515–517.
    CrossRef
  20. Wimmer K, Bolliger M, Bago-Horvath Z, et al. Impact of Surgical Margins in Breast Cancer After Preoperative Systemic Chemotherapy on Local Recurrence and Survival. Ann Surg Oncol. 2020; 27(5): 1700–1707.
    CrossRefPubMed
  21. Levy A, Borget I, Bahri M, et al. Loco-regional control after neo-adjuvant chemotherapy and conservative treatment for locally advanced breast cancer patients. Breast J. 2014; 20(4): 381–387.
    CrossRefPubMed
  22. Curigliano G, Burstein HJ, Winer EP, et al. St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017; 28(8): 1700–1712.
    CrossRefPubMed
  23. Jamaris S, Akpolat-Basci L, Stephanou M, et al. Re-Excision Rates in Breast-Conserving Surgery for Invasive Breast Cancer after Neoadjuvant Chemotherapy with and without the Use of a Radiopaque Tissue Transfer and X-ray System. Breast Care (Basel). 2019; 14(5): 302–307.
    CrossRefPubMed
  24. Ataseven B, Lederer B, Blohmer JU, et al. Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2015; 22(4): 1118–1127.
    CrossRefPubMed
  25. Ueno NT, Espinosa Fernandez JR, Cristofanilli M, et al. International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. J Cancer. 2018; 9(8): 1437–1447.
    CrossRefPubMed
  26. Brzezinska M, Dixon JM. Inflammatory breast cancer: no longer an absolute contraindication for breast conservation surgery following good response to neoadjuvant therapy. Gland Surg. 2018; 7(6): 520–524.
    CrossRefPubMed
  27. Hansson E, Elander A, Hallberg H, et al. Should immediate breast reconstruction be performed in the setting of radiotherapy? An ethical analysis. J Plast Surg Hand Surg. 2020; 54(2): 83–88.
    CrossRefPubMed
  28. Valero MG, Muhsen S, Moo TA, et al. Increase in Utilization of Nipple-Sparing Mastectomy for Breast Cancer: Indications, Complications, and Oncologic Outcomes. Ann Surg Oncol. 2020; 27(2): 344–351.
    CrossRefPubMed
  29. Régis C, Le J, Chauvet MP, et al. Variations in the breast reconstruction rate in France: A nationwide study of 19,466 patients based on the French medico-administrative database. Breast. 2018; 42: 74–80.
    CrossRefPubMed
  30. Sigalove S. Prepectoral breast reconstruction and radiotherapy-a closer look. Gland Surg. 2019; 8(1): 67–74.
    CrossRefPubMed
  31. Riggio E, Toffoli E, Tartaglione C, et al. Local safety of immediate reconstruction during primary treatment of breast cancer. Direct-to-implant versus expander-based surgery. J Plast Reconstr Aesthet Surg. 2019; 72(2): 232–242.
    CrossRefPubMed
  32. Galimberti V, Morigi C, Bagnardi V, et al. Oncological Outcomes of Nipple-Sparing Mastectomy: A Single-Center Experience of 1989 Patients. Ann Surg Oncol. 2018; 25(13): 3849–3857.
    CrossRefPubMed
  33. Pollom EL, Qian Y, Chin AL, et al. Rising rates of bilateral mastectomy with reconstruction following neoadjuvant chemotherapy. Int J Cancer. 2018; 143(12): 3262–3272.
    CrossRefPubMed
  34. Hwang ES, Lichtensztajn DY, Gomez SL, et al. Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status. Cancer. 2013; 119(7): 1402–1411.
    CrossRefPubMed
  35. Corradini S, Reitz D, Pazos M, et al. Mastectomy or Breast-Conserving Therapy for Early Breast Cancer in Real-Life Clinical Practice: Outcome Comparison of 7565 Cases. Cancers. 2019; 11(2): 160.
    CrossRef
  36. Hartmann-Johnsen OJ, Kåresen R, Schlichting E, et al. Survival is Better After Breast Conserving Therapy than Mastectomy for Early Stage Breast Cancer: A Registry-Based Follow-up Study of Norwegian Women Primary Operated Between 1998 and 2008. Ann Surg Oncol. 2015; 22(12): 3836–3845.
    CrossRefPubMed
  37. Fisher S, Gao H, Yasui Y, et al. Survival in stage I-III breast cancer patients by surgical treatment in a publicly funded health care system. Ann Oncol. 2015; 26(6): 1161–1169.
    CrossRefPubMed
  38. Hofvind S, Holen Å, Aas T, et al. Women treated with breast conserving surgery do better than those with mastectomy independent of detection mode, prognostic and predictive tumor characteristics. Eur J Surg Oncol. 2015; 41(10): 1417–1422.
    CrossRefPubMed
  39. Onitilo AA, Engel JM, Stankowski RV, et al. Survival Comparisons for Breast Conserving Surgery and Mastectomy Revisited: Community Experience and the Role of Radiation Therapy. Clin Med Res. 2015; 13(2): 65–73.
    CrossRefPubMed
  40. Chen K, Liu J, Zhu L, et al. Comparative effectiveness study of breast-conserving surgery and mastectomy in the general population: A NCDB analysis. Oncotarget. 2015; 6(37): 40127–40140.
    CrossRefPubMed
  41. Chen QX, Li JJ, Wang XX, et al. The different outcomes between breast-conserving surgery and mastectomy in triple-negative breast cancer: a population-based study from the SEER 18 database. Oncotarget. 2017; 8(3): 4773–4780.
    CrossRefPubMed
  42. Abdulkarim BS, Cuartero J, Hanson J, et al. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol. 2011; 29(21): 2852–2858.
    CrossRefPubMed
  43. Johns N, Dixon JM. Should patients with early breast cancer still be offered the choice of breast conserving surgery or mastectomy? Eur J Surg Oncol. 2016; 42(11): 1636–1641.
    CrossRefPubMed
  44. Agresti R, Sandri M, Gennaro M, et al. Evaluation of Local Oncologic Safety in Nipple-Areola Complex-sparing Mastectomy After Primary Chemotherapy: A Propensity Score-matched Study. Clin Breast Cancer. 2017; 17(3): 219–231.
    CrossRefPubMed
  45. Young WA, Degnim AC, Hoskin TL, et al. Outcomes of > 1300 Nipple-Sparing Mastectomies with Immediate Reconstruction: The Impact of Expanding Indications on Complications. Ann Surg Oncol. 2019; 26(10): 3115–3123.
    CrossRefPubMed
  46. Wengler CA, Valente SA, Al-Hilli Z, et al. Determinants of short and long term outcomes in patients undergoing immediate breast reconstruction following neoadjuvant chemotherapy. J Surg Oncol. 2017; 116(7): 797–802.
    CrossRefPubMed
  47. Adachi Y, Okumura S, Sawaki M, et al. Effects of neoadjuvant chemotherapy on operative adverse events and chemotherapy and radiotherapy in patients undergoing immediate breast reconstruction. Breast Cancer. 2020; 27(4): 716–723.
    CrossRefPubMed
  48. Vidya R, Berna G, Sbitany H, et al. Prepectoral implant-based breast reconstruction: a joint consensus guide from UK, European and USA breast and plastic reconstructive surgeons. Ecancermedicalscience. 2019; 13: 927.
    CrossRefPubMed
  49. Kaplan J, Wagner RD, Braun TL, et al. Prepectoral Breast Reconstruction. Semin Plast Surg. 2019; 33(4): 236–239.
    CrossRefPubMed
  50. Chandarana M, Harries S. National Braxon Audit Study Group. Multicentre study of prepectoral breast reconstruction using acellular dermal matrix. BJS Open. 2020; 4(1): 71–77.
    CrossRefPubMed
  51. Manrique OJ, Charafeddine A, Abu-Ghname A, et al. Two-Staged Implant-Based Breast Reconstruction: A Long-Term Outcome Study in a Young Population. Medicina (Kaunas). 2019; 55(8).
    CrossRefPubMed
  52. Sigalove S, Maxwell GP, Sigalove NM, et al. Prepectoral Implant-Based Breast Reconstruction and Postmastectomy Radiotherapy: Short-Term Outcomes. Plast Reconstr Surg Glob Open. 2017; 5(12): e1631.
    CrossRefPubMed
  53. Sinnott CJ, Persing SM, Pronovost M, et al. Impact of Postmastectomy Radiation Therapy in Prepectoral Versus Subpectoral Implant-Based Breast Reconstruction. Ann Surg Oncol. 2018; 25(10): 2899–2908.
    CrossRefPubMed
  54. Marta GN, Poortmans P, de Barros AC, et al. Multidisciplinary international survey of post-operative radiation therapy practices after nipple-sparing or skin-sparing mastectomy. Eur J Surg Oncol. 2017; 43(11): 2036–2043.
    CrossRefPubMed
  55. Papassotiropoulos B, Güth U, Chiesa F, et al. Prospective Evaluation of Residual Breast Tissue After Skin- or Nipple-Sparing Mastectomy: Results of the SKINI-Trial. Ann Surg Oncol. 2019; 26(5): 1254–1262.
    CrossRefPubMed
  56. Papassotiropoulos B, Güth U, Dubsky P, et al. ASO Author Reflections: A Call for Surgeon Experience and Surgical Radicality to Prevent Residual Breast Tissue After Skin- and Nipple-Sparing Mastectomy. Ann Surg Oncol. 2019; 26(Suppl 3): 694–695.
    CrossRefPubMed
  57. Giannotti DG, Hanna SA, Cerri GG, et al. Analysis of Skin Flap Thickness and Residual Breast Tissue After Mastectomy. Int J Radiat Oncol Biol Phys. 2018; 102(1): 82–91.
    CrossRefPubMed
  58. Herly M, Ørholt M, Larsen A, et al. Efficacy of breast reconstruction with fat grafting: A systematic review and meta-analysis. J Plast Reconstr Aesthet Surg. 2018; 71(12): 1740–1750.
    CrossRefPubMed
  59. Gandhi A, Coles C, Makris A, et al. Axillary Surgery Following Neoadjuvant Chemotherapy - Multidisciplinary Guidance From the Association of Breast Surgery, Faculty of Clinical Oncology of the Royal College of Radiologists, UK Breast Cancer Group, National Coordinating Committee for Breast Pathology and British Society of Breast Radiology. Clin Oncol (R Coll Radiol). 2019; 31(9): 664–668.
    CrossRefPubMed
  60. Thill M, Jackisch C, Janni W, et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. Breast Care (Basel). 2019; 14(4): 224–245.
    CrossRefPubMed
  61. Pilewskie M, Zabor EC, Mamtani A, et al. The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype. Ann Surg Oncol. 2017; 24(12): 3527–3533.
    CrossRefPubMed
  62. de Barros AC, de Andrade DA. Extended Sentinel Node Biopsy in Breast Cancer Patients who Achieve Complete Nodal Response with Neoadjuvant Chemotherapy. Eur J Breast Health. 2020; 16(2): 99–105.
    CrossRefPubMed
  63. Boughey JC. Identifying Residual Nodal Disease in Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy for Breast Cancer. Ann Surg Oncol. 2019; 26(12): 3794–3797.
    CrossRefPubMed
  64. Barrio AV, Mamtani A, Edelweiss M, et al. How Often Is Treatment Effect Identified in Axillary Nodes with a Pathologic Complete Response After Neoadjuvant Chemotherapy? Ann Surg Oncol. 2016; 23(11): 3475–3480.
    CrossRefPubMed
  65. Samiei S, van Nijnatten TJA, de Munck L, et al. Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy. Ann Surg. 2020; 271(3): 574–580.
    CrossRefPubMed
  66. Classe JM, Loaec C, Gimbergues P, et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat. 2019; 173(2): 343–352.
    CrossRefPubMed
  67. Mamounas EP, Anderson SJ, Dignam JJ, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol. 2012; 30(32): 3960–3966.
    CrossRefPubMed
  68. Kuru B. The Adventure of Axillary Treatment in Early Stage Breast Cancer. Eur J Breast Health. 2020; 16(1): 1–15.
    CrossRefPubMed
  69. Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2018; 29(10): 2153.
    CrossRefPubMed
  70. American Society of Breast Surgeons. Position Statement on Management of the Axilla in Patients With Invasive Breast Cancer. 2011: 1–4.
  71. Samiei S, van Kaathoven BN, Boersma L, et al. Risk of Positive Sentinel Lymph Node After Neoadjuvant Systemic Therapy in Clinically Node-Negative Breast Cancer: Implications for Postmastectomy Radiation Therapy and Immediate Breast Reconstruction. Ann Surg Oncol. 2019; 26(12): 3902–3909.
    CrossRefPubMed
  72. Di Micco R, Zuber V, Fiacco E, et al. Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype. Eur J Surg Oncol. 2019; 45(6): 969–975.
    CrossRefPubMed
  73. Nguyen TT, Hoskin TL, Day CN, et al. Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Ann Surg Oncol. 2018; 25(9): 2596–2602.
    CrossRefPubMed
  74. Cardoso F, Kyriakides S, Ohno S, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019; 30(8): 1194–1220.
    CrossRefPubMed
  75. Burstein HJ, Curigliano G, Loibl S, et al. Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019; 30(10): 1541–1557.
    CrossRefPubMed
  76. Shirzadi A, Mahmoodzadeh H, Qorbani M. Assessment of sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer in two subgroups: Initially node negative and node positive converted to node negative - A systemic review and meta-analysis. J Res Med Sci. 2019; 24: 18.
    CrossRefPubMed
  77. Pilewskie M, Morrow M. Axillary Nodal Management Following Neoadjuvant Chemotherapy: A Review. JAMA Oncol. 2017; 3(4): 549–555.
    CrossRefPubMed
  78. Moo TA, Edelweiss M, Hajiyeva S, et al. Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection? Ann Surg Oncol. 2018; 25(6): 1488–1494.
    CrossRefPubMed
  79. Moo TA, Edelweiss M, Hajiyeva S, et al. Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection? Ann Surg Oncol. 2018; 25(6): 1488–1494.
    CrossRefPubMed
  80. Caudle AS, Gonzalez-Angulo AM, Hunt KK, et al. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010; 28(11): 1821–1828.
    CrossRefPubMed
  81. Wu S, Wang Y, Zhang Na, et al. Intraoperative Touch Imprint Cytology in Targeted Axillary Dissection After Neoadjuvant Chemotherapy for Breast Cancer Patients with Initial Axillary Metastasis. Ann Surg Oncol. 2018; 25(11): 3150–3157.
    CrossRefPubMed
  82. Mamtani A, Barrio AV, King TA, et al. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study. Ann Surg Oncol. 2016; 23(11): 3467–3474.
    CrossRefPubMed
  83. Laws A, Hughes ME, Hu J, et al. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Ann Surg Oncol. 2019; 26(12): 3846–3855.
    CrossRefPubMed
  84. Green M, Neamonitou F, Vidya R. Conservative Management of Positive Axilla After Neoadjuvant Systemic Therapy-The Need for, and Review of, Techniques Used for Lymph Node Localization. Clin Breast Cancer. 2018; 18(5): e739–e742.
    CrossRefPubMed
  85. Banys-Paluchowski M, Gruber IV, Hartkopf A, et al. Axillary ultrasound for prediction of response to neoadjuvant therapy in the context of surgical strategies to axillary dissection in primary breast cancer: a systematic review of the current literature. Arch Gynecol Obstet. 2020; 301(2): 341–353.
    CrossRefPubMed
  86. Siso C, de Torres J, Esgueva-Colmenarejo A, et al. Intraoperative Ultrasound-Guided Excision of Axillary Clip in Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Therapy (ILINA Trial) : A New Tool to Guide the Excision of the Clipped Node After Neoadjuvant Treatment. Ann Surg Oncol. 2018; 25(3): 784–791.
    CrossRefPubMed
  87. Namura M, Tsunoda H, Kobayashi D, et al. The Loss of Lymph Node Metastases After Neoadjuvant Chemotherapy in Patients With Cytology-proven Axillary Node-positive Primary Breast Cancer. Clin Breast Cancer. 2019; 19(4): 278–285.
    CrossRefPubMed
  88. Caudle AS, Bedrosian I, Milton DR, et al. Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members. Ann Surg Oncol. 2017; 24(10): 2925–2934.
    CrossRefPubMed
  89. Bilimoria KY, Bentrem DJ, Hansen NM, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009; 27(18): 2946–2953.
    CrossRefPubMed
  90. Bonneau C, Hequet D, Estevez JP, et al. Impact of axillary dissection in women with invasive breast cancer who do not fit the Z0011 ACOSOG trial because of three or more metastatic sentinel lymph nodes. Eur J Surg Oncol. 2015; 41(8): 998–1004.
    CrossRefPubMed
  91. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007; 25(28): 4414–4422.
    CrossRefPubMed
  92. Pinder SE, Provenzano E, Earl H, et al. Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy. Histopathology. 2007; 50(4): 409–417.
    CrossRefPubMed
  93. Bantema-Joppe EJ, Vredeveld EJ, de Bock GH, et al. Five year outcomes of hypofractionated simultaneous integrated boost irradiation in breast conserving therapy; patterns of recurrence. Radiother Oncol. 2013; 108(2): 269–272.
    CrossRefPubMed
  94. Schubert L, Gondi V, Sengbusch E, et al. Dosimetric comparison of left-sided whole breast irradiation with 3DCRT, forward-planned IMRT, inverse-planned IMRT, helical tomotherapy, and topotherapy. Radiother Oncol. 2011; 100(2): 241–246.
    CrossRefPubMed
  95. Latty D, Stuart KE, Wang W, et al. Review of deep inspiration breath-hold techniques for the treatment of breast cancer. J Med Radiat Sci. 2015; 62(1): 74–81.
    CrossRefPubMed
  96. Haviland JS, Owen JR, Dewar JA, et al. START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013; 14(11): 1086–1094.
    CrossRefPubMed
  97. Haffty BG. Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer. Breast Diseases: A Year Book Quarterly. 2010; 21(3): 267–268.
    CrossRef
  98. Valachis A, Mamounas EP, Mittendorf EA, et al. Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis. Cancer. 2018; 124(14): 2923–2930.
    CrossRefPubMed
  99. Gałecki J, Hliniak A, Bujko K, et al. Wczesne wyniki pooperacyjnej radioterapii w skróconym czasie u chorych na raka piersi - Badanie populacyjne. Nowotwory. 2007; 57: 20–28.
  100. Gałecki J, Nagadowska M, Pieńkowski T, et al. i in. Przeżycie i czynniki prognostyczne u chorych na wczesnego raka piersi po leczeniu oszczędzającym w dwóch okresach leczenia: przed i po wprowadzeniu łagodnej hipofrakcyjnej radioterapii i zintensyfikowanej chemioterapii pooperacyjnej. Nowotwory J Oncol. 2012; 62: 85–93.
  101. Recht A, Comen EA, Fine RE, et al. Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. J Clin Oncol. 2016; 34(36): 4431–4442.
    CrossRefPubMed
  102. Akyurek S, Yavas G. Role of postmastectomy radiation therapy after neoadjuvant chemotherapy in locally advanced breast cancer. Exp Oncol. 2013; 35(4): 267–271.
    PubMed
  103. Francis SR, Frandsen J, Kokeny KE, et al. Outcomes and utilization of postmastectomy radiotherapy for T3N0 breast cancers. Breast. 2017; 32: 156–161.
    CrossRefPubMed
  104. Johnson ME, Handorf EA, Martin JM, et al. Postmastectomy radiation therapy for T3N0: a SEER analysis. Cancer. 2014; 120(22): 3569–3574.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl